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ABSTRACT 
Introduction: Osteoporosis has been recognised as an established and well-defined disease that 
affects more than 75 million people in the United States, Europe and Japan. Osteoporosis has been 
operationally defined by the WHO on the basis of bone mineral density (BMD) assessment. Although 
risk factors for fracture are well-known and thoroughly investigated, osteoporosis is an under-
diagnosed and under-treated disease in women, and even more so in men.  
Objective: The general objective of this work is in the context of the development an assessment tool 
(FRAX) for the prediction of fracture in men and women with the use of clinical risk factors for 
fracture with and without the use of femoral neck BMD. The rationale arises from the observation that 
factors other than BMD contribute towards fracture risk and that estimates of probability permit the 
integration of multiple clinical risk factors (CRFs) including the competing risk of death. The material 
presented in this thesis aims to illustrate several components of this work. The first is the identification 
of a clinical risk factor (exposure to glucocorticoids) as a potential candidate for its inclusion into the 
FRAX algorithm. A second aim was to determine the increase in operating characteristics of 
combining clinical risk factors with and without the inclusion of BMD. A novel feature of the FRAX 
models is that they integrate the fracture and death hazards in the determination of fracture 
probabilities. Several clinical risk factors affect the death hazard as well as the fracture hazard, so that 
a third aim was to explore the effect of a well established CRF (BMD) and a potential CRF (serum 25-
hydroxyvitamin D) on the risk of death. A final aim was to determine the potential of a new candidate 
risk variable (serum adiponectin) for fracture.  
Methods: To create the risk assessment tool baseline and follow-up data is used from eleven 
international prospective population-based cohorts comprising 15 259 men and 44 902 women with 
5 563 fractures of any kind and 978 hip fractures. Cohorts were followed for a total of over 250 000 
person years. Primary data from the cohorts is used so that important interactions could be determined. 
In addition a Swedish cohort of 3 014 elderly men (MrOS) is used, drawn from the general population.  
Results: The risk factors incorporated in the assessment tool comprised body mass index (as a 
continuous variable), a prior history of fracture, a parental history of hip fracture, use of oral 
glucocorticoids, rheumatoid arthritis, current smoking and alcohol intake >2 units daily. Their 
inclusion was based on their international validity and independent contribution to fracture risk. Four 
models were then constructed to compute fracture probabilities in nine of the cohorts. These 
comprised the probability of hip fracture, with and without femoral neck BMD, and the probability of 
other osteoporotic fractures, with and without BMD. For each model fracture and death hazards 
functions were computed and used to compute 10-year fracture probabilities (FRAX). The model 
could be calibrated to any country where the epidemiology of fracture and death is known. In the 
publications included in this thesis, exposure to glucocorticoids is shown to be a significant risk factor 
for fracture, providing the rational for the inclusion of this CRF in the FRAX algorithms. We also 
show that the incorporation of CRFs improves the operating characteristics of fracture risk assessment 
over and above that provided by BMD alone. In elderly men in the Swedish MrOS cohort, it is shown 
that low BMD is associated with increased mortality in a non-linear pattern (overall gradient of risk 
(GR) 1.27; 95% CI 1.14-1.42, multivariable adjusted), that low vitamin D is associated with increased 
mortality (overall GR; 1.15; 95% CI 1.03-1.29, multivariable adjusted) and that the association wanes 
with time. It is also shown that high adiponectin is associated with higher fracture risk in elderly men 
(overall GR; 1.32; 95% CI 1.15-1.52, multivariable adjusted).  
Conclusion: Components of the work in this thesis have contributed to the creation of FRAX, a 
fracture risk assessment tool, that has been recommended by WHO and is widely used in clinical 
practice to identify patients suitable for pharmacological intervention. In elderly men it is showed that 
low BMD and low vitamin D are risk factors for death and high adiponectin is a risk factor for 
fracture. The biostatistical contribution to these associations is the identification of non-linearity of the 
associations and their dependence on time since baseline assessment. 
Keywords: osteoporosis, fracture, bone mineral density, clinical risk factors, FRAX, Poisson model, 
10 year probability, mortality, vitamin D, adiponectin  
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Abbreviations and explanations 
 
25(OH)D   25-hydroxy-vitamin D 
CRF  clinical risk factor 
BMD   bone mineral density 
BMI   body mass index (kg/m2). Calculated: weight in kg / height in m2 
BUA   broad-band ultrasound attenuation  
CI   confidence interval 
DXA  dual-energy X-ray absorptiometry 
FRAX   WHO fracture assessment tool 
GR   gradient of risk, hazard ratio per one SD change 
HR  hazard ratio 
ICD 10   International Classification of Diseases, Revision 10 (1990) 
MrOS   study of osteoporotic fractures in men 
QUS   quantitative ultrasound  
SD  standard deviation 
SoS   speed of sound (or ultrasound velocity) 
T-score Bone density values in individuals expressed in relation to the 
young healthy population in standard deviation units.  
WHO  World Health Organization 
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Introduction 
 
Risk 
In epidemiology, a risk factor is a variable associated with an increased risk of disease. Risk 
factors are correlational and not necessarily causal, because correlation does not imply 
causation. Risk factors are evaluated by comparing the risk of those exposed to the potential 
risk factors to those not exposed. The term “risk factor” was first coined by heart researcher 
Thomas Dawber in a scientific paper in 1961, where he attributed heart disease to specific 
conditions (blood pressure, cholesterol and smoking). More generally, a risk variable can be 
considered, which is allowed to be discrete or continuous, and study the relationship for the 
risk of an event.  
 
Survival analysis examines the time it takes for events to occur. The prototypical event is 
death, from which the name “survival analysis” and much of its terminology derives, but the 
application of survival analysis is much broader. Survival analysis focuses on the distribution 
of survival times. A basic notion of survival analysis is hazard function, which describes the 
momentary risk of an event. Survival time assumes a starting point from which the survival is 
counted. By use of hazard functions risk can be studied without survival times and thus the 
applicability can be extended. Cox proportional-hazards regression model (introduced in a 
seminal paper by Cox, 1972)1, is a broadly applicable and the most widely used method of 
survival analysis. The proportional hazard requirement of the Cox model means that the 
hazard ratio when comparing a value of a risk variable with another value is not dependent on 
time. This may sometimes be a serious limitation when it is relevant to study the predictive 
ability of a risk variable with time or when a treatment effect changes with duration of 
treatment. From a mathematical point of view, the proportional hazards requirement can be 
described as follows: The β-coefficients must not depend on time. For the studies in the 
present thesis, a method is applied which overcome the restriction of proportional hazards 
referred to the method as a Poisson regression analysis2. Some comments are needed to 
explain how Poisson regression was presented in Breslow and Day2 and how it has been used 
to estimate a continuous hazard function. In Breslow and Day the intention was to estimate 
the expected number of events, e.g. the number of diseased, depending on variables that 
characterize subpopulations. Our aim has been to estimate hazard functions.  
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The follow-up period of each individual is divided in to small intervals. The number of events 
of an individual in an interval is 0 or 1, the last mentioned value is attained with a low 
probability. The distribution of such a variable coincides almost exactly with a Poisson 
distribution. That will not always be the case if the intervals are wide or the number of events 
include several individuals. In Breslow and Day2 they did not confine the model building to 
one individual at a time and small intervals ensure Poisson distribution.  
 
Studies of risk in the medical field are often a collaboration between experts in medicine and 
statistics. On rare occasions statisticians can contribute with novel methods, which elucidate 
new aspects of risk variables and allows the complex use of them. In this thesis, some novel 
methods have been applied to determine whether a relative change in risk is the same for an 
increase of 1 unit from the value x of the risk variable independently of x. The same 
principles can be used to study if there is an interaction between a risk variable and time. 
Whereas the traditional methods generate a simple hazard ratio only, these new methods can 
produce functions of time or of the risk variable or both. Finally the methods permit 
estimation of continuous hazard functions, which can be used in several applications.  
 
Osteoporosis  
Osteoporosis has been recognised as an established and well-defined disease that affects more 
than 75 million people in the United States, Europe and Japan. Osteoporosis causes more than 
8.9 million fractures annually world-wide of which more than 4.5 million occur in the 
Americas and Europe. The life-time risk for a forearm, hip or vertebral fracture has been 
estimated to be in the order of 30 to 40% in the Western World – in other words, very close to 
that for cardiovascular disease. Osteoporosis is not only a major cause of fractures, it also 
ranks high among diseases that cause people to become bedridden with serious complications. 
These may be life threatening in the elderly. Because of the morbid consequences of 
osteoporosis, the prevention of this disease and its associated fractures is considered essential 
to the maintenance of health, quality of life, and independence in the elderly population.  
 
Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) 
assessment. A WHO study group that was chaired by Prof John Kanis defined osteoporosis in 
1994 for postmenopausal women as a BMD that lies 2.5 standard deviations or more below 
the average value for young healthy women (a T-score of <-2.5 SD)3 4. This criterion has been 
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widely accepted and, in many countries, provides both a diagnostic and intervention 
threshold. Suitable diagnostic cut-off values for osteoporosis in men have been less well 
defined. Many investigators and equipment manufacturers have reported T-score values that 
use a male reference range, which in turn has led to a T-score of -2.5SD being used widely as 
a diagnostic criterion also for men. The most widely validated technique to measure BMD is 
dual energy X-ray absorptiometry (DXA) in hip and lumbar spine, and diagnostic criteria, 
based on the T-score for BMD are a recommended entry criterion for the development of 
pharmaceutical interventions in osteoporosis. The implication is that BMD should be assessed 
before treatment is considered.  
 
There are, however, problems with the use of BMD tests alone. In many countries, BMD tests 
using DXA are not widely available, or are used predominantly for research, in part because 
of the high capital costs of DXA. Another problem with the use of BMD tests alone is that 
they can only capture one aspect of the risk of fracture in a disease that is multifactorial. In the 
case of osteoporosis, assessment with BMD captures a minority of the fracture risk. For 
example the annual incidence of hip fracture increases approximately 30-fold between the 
ages of 50 and 90 years, but from the known relationship between BMD and fracture risk and 
the loss of bone with age, it is expected that hip fracture risk would rise only 4-fold5-7. Thus, 
the increase in risk with age is approximately 7-times greater than can be explained on the 
basis of bone mineral density alone.  
 
The imperfect capture of risk with BMD alone poses several problems. In the context of 
population screening with BMD alone, the performance characteristics of the test are 
inadequate in terms of the trade-off between sensitivity and specificity 4 8. Osteoporotic 
fractures affect a substantial minority of the population, and intervention thresholds based on 
BMD alone lack sensitivity over most reasonable assumption – i.e. the detection rate is low. 
The use of other risk factors for fracture in addition to BMD improves sensitivity without 
adverse effects on specificity 8. Against this background there has been interest in computing 
risk of clinical outcomes based on combinations of risk factors 8 9. Indeed, it is suggested that 
intervention thresholds in osteoporosis should be based on fracture probabilities rather than 
the fulfilment of diagnostic criteria using BMD alone 10. This approach also enfranchises all 
risk factors of proven clinical utility, as has been done for cardiovascular disease 11 12. 
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Estimation of risk 
Conroy et al determined the 10-year probability of fatal cardiovascular disease as a function 
of age, blood pressure and cholesterol (SCORE)13. The UKPDS group14 has determined the 
probability of coronary heart disease among patients with Type II diabetes depending on a set 
of variables. The same group has also determined the probability of stroke as a function of 
age, race, smoking, body mass index, atrial fibrillation, HbA1c, systolic blood pressure, ratio 
of total to HDL cholesterol and duration of diabetes. In these examples, the risk of dying from 
other reasons was not taken into account. Thus they have for example calculated the risk of 
stroke (fatal or non fatal), which does not allow for the fact that the patients might die for 
other reasons. This limitation is inappropriate in the case of hip fracture for instance, since hip 
fracture is common among people at very high age. The same would hold true for elderly 
patients with diabetes. In such cases it would also be appropriate to calculate the probability 
of stroke taking the risk of dying into account. In the context of osteoporosis, there are two 
tools other than FRAX for fracture risk calculation, QFracture™ (www.qfracture.org) based 
on a UK cohort15 and the Garvan tool (www.garvan.org.au) based on a cohort from 
Australia16 17. Both uses Cox proportional hazard regression models and neither take account 
of the competing risk of death.  
 
A further problem in the construction of risk assessment models relates to the use of hazard 
functions determined for one geography to other countries where the hazards of death and 
disease events differ. The incidence of hip fracture varies 15-fold around the world18 and to be 
able to use the fracture probability estimated from an international setting to a specific 
country, a modification of the probability has to be done according to the country-specific 
epidemiology.  
 
In the past decade, a great deal of research has taken place to identify factors other than BMD 
that contribute to fracture risk. Examples include age, sex, the degree of bone turnover, a prior 
fracture, a family history of fracture and lifestyle risk factors such as physical inactivity and 
smoking. Some of these risk factors are partially or wholly independent of BMD. Independent 
risk factors used with BMD could, therefore, enhance the information provided by BMD 
alone. Conversely, some strong BMD-dependent risk factors can, in principle, be used for 
fracture risk assessment in the absence of BMD tests. For this reason, the consideration of 
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well-validated risk factors, with or without BMD, is likely to improve fracture prognostication 
and the selection of individuals at high risk for treatment.  
 
In this thesis the work on constructing WHO fracture assessment tool (FRAX) is described. 
FRAX is based on 11 prospectively studied population-based cohorts. In those cohorts there 
was 25% men (n=15 259). The Osteoporotic Fractures in Men (MrOS) Study is a prospective 
cohort study designed to provide information about osteoporosis and fracture risk in men. The 
MrOS cohort is studied in this thesis to elucidate risk factors for fracture and death in men.  
 
Vitamin D 
Vitamin D is recognized to be an active hormone with endocrine and paracrine effects on 
many organs and tissues of the body. The two natural sources of vitamin D are sunlight and 
nutrition19 20. Vitamin D3 (cholecalciferol) is the form of vitamin D that is synthesized in the 
skin under the influence of ultraviolet B (UVB) rays; it is also found in certain fish, fortified 
dairy products, and most dietary supplements. Vitamin D2 (ergocalciferol) is produced by 
irradiated fungi and is the form of vitamin D found in some prescription supplements. After 
vitamin D is formed in the skin, it is converted to 25(OH)D (calcidiol) in the liver. This 
transport and storage form of vitamin D then circulates to the kidneys, where it is converted to 
the active form (1α,25[OH]2D); calcitriol). Calcitriol is the active form of vitamin D, which 
binds to vitamin D receptors in intestines, bones, and kidneys to increase calcium absorption 
from the intestines, promote calcium deposition in bones and decrease parathyroid hormone 
concentration (PTH). The transport and storage form of vitamin D, 25(OH)D, is measured to 
assess the vitamin D sufficiency status of persons. Several studies have described a 
relationship between 25(OH)D and the risk of death21-35.  
 
Adiponectin 
Adiponectin is a protein hormone mainly produced by adipocytes (fat cells) that regulates a 
number of metabolic processes, including glucose regulation and fatty acid catabolism. 
Adiponectin influences the body’s response to insulin. Adiponectin is secreted into the 
bloodstream where it accounts for approximately 0.01% of all plasma protein. In cross 
sectional studies, higher serum adiponectin has generally been associated with lower BMD 
values in women36-46. There are five studies about adiponectin and fracture risk, two cross-
sectional studies47 48 and three prospective studies42 49 50. The studies that included women 
  
  
  14 
found no significant association between adiponectin and risk of fracture 42 47 48 50. Three 
studies found a positive significant association between adiponectin and risk of fracture 
among men42 48 50 whilst one study found no significant interaction49.  
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Aim 
 
The general aims of this thesis were to identify and validate clinical risk factors for use in 
fracture risk assessment on an international basis, either alone, or in combination with bone 
mineral tests. Both risk factors for fracture and death are identified. A further aim was to 
develop algorithms for risk assessment (FRAX) that were sufficiently flexible to be used in 
the context of many primary care settings, including those where BMD testing was not readily 
available. Further general aim was to investigate other risk variables for fracture and death in 
a setting of elderly men.  
 
The specific aims were: 
 
I. To examine, in an international setting, the association between glucocorticoid use 
and fracture risk, in men and women and to determine its dependence on other risk 
factors. 
  
II. Utilise the primary data from the eleven international cohorts to determine the 
impact of the addition of multiple clinical risk factors to BMD for the prediction of 
fractures, and to validate the findings using data from independent cohorts. 
 
III. To investigate the relationship between BMD and mortality in elderly men in 
MrOS cohort, Sweden. 
 
IV. To investigate the relationship between vitamin D and mortality in elderly men in 
MrOS cohort, Sweden. 
 
V. To investigate the relationship between adiponectin and risk of fracture in elderly 
men MrOS cohort, Sweden. 
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Patients and methods 
 
60 161 persons are studied, 15 259 men and 44 902 women from 11 prospectively studied 
cohorts with 5 563 fractures of any kind and 978 hip fractures. Cohorts were followed for a 
total of over 250 000 person years. Brief details of the cohorts studied are given below more 
extensively descriptions are given in paper I and II. 
 
OFELY 
The OFELY cohort comprises an age-stratified cohort of 1 039 women aged 31-89 years 
randomly selected from the regional section of a large health insurance company (Mutualle 
Generale d’Education Nationale, Lyon) 51. Eighteen percent of women contacted participated 
in the study.  
 
EVOS 
The European Vertebral Osteoporosis Study (EVOS) comprised age- and sex-stratified 
random samples from 36 centres in 19 European countries 52-54. Equal numbers of men and 
women were drawn in each centre within six 5-year age bands (50-54 to 75-79 years).  
 
CaMos 
The Canadian Multicentre Osteoporosis Study (CaMos) is an on-going prospective age-
stratified cohort. The study is documenting the incidence of fractures and risk factors in a 
random sample of 9 424 men and women aged 25 years or more selected by telephone 
listings. The sampling frame is from 9 study centres in 9 provinces 55.  
 
Rochester 
The Rochester cohort was recruited from two random US population samples stratified by 
decade of age, one comprising women who were subsequently followed for up to 20 years 56 
and another sample of women and men followed for 8 years 57.  
 
Sheffield 
The Sheffield cohort comprised women aged 75 years or more selected randomly from the 
population of Sheffield, UK, and surrounding districts between 1993 and 1999. The women 
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were randomly allocated to treatment with the bisphosphonate clodronate, or to an identical 
placebo. The present paper comprised 2148 women allocated to treatment with placebo 58.  
 
Rotterdam 
The Rotterdam study, begun in 1990, is a prospective cohort study that aimed to examine and 
follow-up all residents aged 55 years and older living in Ommoord, a district of Rotterdam 59 
60. For this analysis, validated fracture follow up was available for 7774 participants (3065 
men) with an average follow up time of 6 years.  
 
Kuopio 
The Kuopio osteoporosis risk factor and prevention (OSTPRE) study in Finland comprised a 
postal enquiry sent to all 14,220 women aged 47-56 who were residents of Kuopio province 
in 1989. 13,100 women responded to the enquiry, of whom 1214 were excluded for 
incomplete information. This left a study population of 11,886 women61. 
 
Gothenburg I 
This study comprised 4 birth cohorts of 2375 randomly sampled men and women aged 70 
years or more followed for up to 20 years at Gothenburg 62 63 after a base-line BMD 
measurement. The participants were drawn randomly from the population register in 
Gothenburg by the date of birth to provide cohorts aged 70, 76, 79 and 85 years at the time of 
investigation.  
 
Gothenburg II 
The Gothenburg study comprised a randomly drawn population cohort of women aged 21-89 
years followed up to 7.9 years (mean 4.2 years)64. 70% of those invited (approximately 7000 
women) participated in the study that examined risk factors for osteoporosis.  
 
DOES 
The DOES Osteoporosis Epidemiology Study (DOES) is a population-based study with 
multiple assessments of skeletal status in men and women aged 60 years or more from DOES, 
Australia 65. Participation in the study was 56% of the population.  
 
Hiroshima 
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The Adult Health Study in Hiroshima (AHS) documents the late health effects of radiation 
exposure among atomic bomb survivors in Hiroshima and Nagasaki. AHS subjects have been 
followed through biennial medical examinations since 1958 with a participation rate of 
approximately 80% throughout this period 66 67. 
 
In paper I just EVOS, CaMos, Rotterdam, DOES, Sheffield, Rochester and Gothenburg II is 
used since the baseline assessment in these cohorts included questions about the use of 
glucocorticoids.  
 
In paper II all cohorts except Ofely and Kuopio were used. These two cohorts were excluded 
since they didn’t have enough clinical risk factors available in their baseline assessment. For 
evaluation of the risk score additional independent cohorts were used; EPIDOS, PERF, THIN, 
OPUS, York, SOF, Geelong I, Geelong II, Miyama, SEMOF and WHI described in more 
detail in paper II.  
 
In paper III and IV MrOS Sweden is used, a multi-centre study including elderly men aged 
70-80 years. The cohort was conducted with the aim of getting more information on 
osteoporosis and risk factors for osteoporosis in men. In paper V just the part from 
Gothenburg in MrOS is used. Participants in MrOS Sweden were randomly identified using 
national population registers. To be eligible for the study, men had to be able to walk without 
aids, provide self-reported data and give signed informed consent. The participation rate was 
45%. MrOS Sweden is part of a multicentre study including men in Sweden (n=3014), Hong 
Kong (n=2000) and the United States (n=6000). More details are given in paper III-V. 
 
Baseline and outcome variables 
In the cohorts a questionnaire was answered at baseline. This questionnaire were not 
standardized between cohorts and the clinical risk factors analysed could be present or not and 
the questions could be differently asked. 
 
Paper I focused on ever oral glucocorticoid use, because the questionnaire in most cohorts did 
not distinguish between ever and current use.  
EVOS – ever use for more than 3 months 
CaMos – ever use of more than 1 month 
  
  
  19 
Rotterdam – current use and noncurrent use  
DOES – never use, past use and current use 
Sheffield – never use, ever use and current use 
Rochester - ever use of more than 6 months 
Gothenburg II – ever use of more than 3 months  
 
BMD was assessed at the femoral neck by DXA with the exception of the two cohorts from 
Gothenburg where BMD was assessed by DXA at the distal forearm. 
 
The fracture outcome during follow up were divided into three categories; any fracture, hip 
fracture and osteoporotic fracture. These categories could look somewhat different for 
different cohorts but any fracture was all fractures reported and an osteoporotic fracture that 
was one considered to be characteristic for osteoporosis68. When a country specific model is 
made for the ten year risk of fracture, the ten year risk of a major osteoporotic fracture and the 
ten year risk of a hip fracture is calculated. A major osteoporotic fracture is a clinical spine, 
hip, humeral or forearm fracture. A clinical spine fracture is defined as ICD 10 codes S12.0 
(Fracture of first cervical vertebra), S12.1 (Fracture of second cervical vertebra), S12.2 
(Fracture of other specified cervical vertebra), S22.0 (Fracture of thoracic vertebra), S22.1 
(Multiple fractures of thoracic spine), S32.0 (Fracture of lumbar vertebra) and T08 (Fracture 
of spine, level unspecified). A humeral fracture is defined as ICD 10 codes S42.2 (Fracture of 
upper end of humerus) and S42.3 (Fracture of shaft of humerus). A forearm fracture is ICD 10 
codes S52.5 (Fracture of lower end of radius) and S52.6 (Fracture of lower end of both ulna 
and radius). A hip fracture comprised ICD 10 codes S72.0 (Fracture of neck of femur), S72.1 
(Pertrochanteric fracture) and S72.2 (Subtrochanteric fracture).  
 
Statistical methods 
All analyses are made using the primary data from the different cohorts. When investigating  
associations between risk factors and fracture or death from primary data, the relationships 
between risk factors and BMD could be explored. The use of primary data also lessens the 
risk of publication bias.  
  
This method allows the estimation of the association between risk factors and fracture or 
death to be estimated in relation to each other  
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The estimated hazard functions for fracture and death were of the form exp( b0 + b1 ×time 
since assessment + b2 ×age + b3 ×Risk factor + b4 ×BMD). They were estimated as continuous 
functions by Poisson regression 2 69.  
  
The risk of fracture was estimated by Poisson regression model applied to each cohort and sex 
separately. Covariates always included time since start of follow up and current age. BMD 
was additionally excluded from the model. A further model included the interaction term 
between risk factor and age (bk ×Risk factor×age), the interaction term between risk factor and 
time (bk ×Risk factor×time) or the interaction with the risk factor itself (bk ×Risk factor2), the 
latter was done just for the continuous variables. Results of each cohort and the two sexes 
were weighted according to the variance and merged to determine the weighted mean and 
standard deviations.  
 
Each variable that could be a candidate to be a risk factor was examined in the eleven cohorts. 
The β-coefficients from the different cohorts were merged together as describe above. When a 
risk factor was absent in one cohort, the β-coefficients for the other risk factors were treated 
as if the cohort had information on all risk factors. This could be done since the influence on 
the β-coefficient of a risk variable, which has a non-dominating effect on the risk, is small. 
Only BMD has a dominating effect in this context. The factors that had a significant 
relationship with the risk of fracture were used to develop a hazard function for the risk of 
fracture.  
 
The relationship between probability and hazard functions were then used to calculate the 10-
year probability or fracture for a combination of the risk factors. Let h(t) denote the fracture 
hazard function, d(t) the death hazard function and g(t) the hazard function of the combined 
event hip fracture or death. Though the functions in typical applications contain several 
variables, only a time variable is given in order to simplify the notations. The hazard function 
g of having the first event of death or hip fracture is well approximated by d + h. From the 
general and well-known relationship between survival and hazard functions it is known that 
the probability of being free from any of the two types of events at the end of the period (0,t) 
is 
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When taking account of the hazard function of death in the calculation of 10 year probability, 
as showed above, the risk of death is taken account of twice, i.e. as a hazard function and also 
as a censoring factor when looking at the time to fracture when applying the Poisson model.  
 
Four models were constructed from the risk factor analysis to compute fracture probabilities. 
These comprised the probability of hip fracture, with and without BMD, and the probability 
of other major osteoporotic fractures, with and without BMD. For each model, fracture and 
death as continuous hazard functions were computed using a Poisson regression as previously 
described. For each risk factor, all significant interactions terms that were identified by meta-
analysis were entered (with age, time, sex and the risk factor) with and without BMD. 
Interactions that were significant for hip fracture risk were also entered into the model for 
other osteoporotic fractures, and also included in the model for death. Where interactions 
noted in the “mega-analyses” were no longer significant for both hip fracture and other 
osteoporotic fractures, these were omitted in a step-wise manner by dropping the interaction 
with the largest p value. For the death hazard, all significant interactions for fracture risk were 
included and thereafter omitted if appropriate in a step-wise manner, as described for the 
fracture hazard.  
 
The hazard functions given above were estimated by use of the eleven cohorts. If it is 
assumed that the relative importance of the risk variables is the same for all countries, e.g., we 
can use hazard functions of the form 
 
exp( b1 ∙ time since assessment + bi×risk factori) × z(age) × hazard function of Sweden,  
 
where z(age) is a factor depending on age equal to 1/ E[exp(bi ∙ risk factori)½age], i.e. 1 
divided by the conditional expected value of exp(bi ∙ risk factori) given the value of age. If a 
random variable Y has a normal distribution with the mean m and standard deviation s then 
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E[exp(Y)] = exp(m+s2/2). Denote Y = b1 time since assessment + bi ∙ risk factori. By linear 
regression (in the simplest case) we determine E[Y½age] = a + b × age and the standard 
deviation s around the regression line. Then z(age) can be put equal to 1/exp(a + b × age + 
s2/2). 
 
Poisson regression models were also used to explore the relationships between mortality and 
BMD, mortality and Vitamin D plus fracture risk and adiponectin. A spline Poisson 
regression model was fitted using knots at certain percentiles points of BMD, vitamin D and 
adiponectin. The interaction between time since baseline and the risk variable studied was 
also used to elucidate the state of the relationship in both a linear (adiponectin) and non-linear 
shape. 
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Results 
 
I and II: FRAX 
For calculating the 10 year probability of fracture, the 11 cohorts, described in table 1 were 
used.  
 
Table 1. Details of cohorts studied by meta-analysis of risk factors. 
Cohort  Sample 
size 
Person- 
years 
Mean 
age 
(years) 
Age 
range 
(years) 
% 
female 
Fracture 
history 
% 
Any 
fracture 
Osteoporotic 
fracture 
Hip 
fracture 
           
EVOS  13366 40160 63.8 41-91 52 36 715 715 44 
OFELY  426 2124 64.2 50-89 100 16 53 - - 
CaMos  9400 26653 62.1 25-103 69 44 586 316 42 
Rochester  1001 6228 56.8 21-94 65 18 289 244 42 
Sheffield  2147 6826 80.0 74-96 100 51 284 236 62 
Rotterdam  7774 43606 70.3 55-106 61 14 992 768 284 
Kuopio  11798 56602 52.3 47-57 100 17 1053 - - 
Gothenburg 
I 
 2375 16439 78.8 69-86 61 9 431 431 336 
Gothenburg 
II 
 7098 29750 58.9 21-89 100 18 441 312 29 
DOES  2163 16333 70.7 57-96 61 15 532 418 107 
Hiroshima  2613 9861 65.1 47-95 70 26 187 90 32 
           
Totals  60161 254582 62.9 21-106 75 26 5563 3530 978 
 
As a start a list was made of candidate risk factors, factors that possibly could have 
importance for the risk of fracture. Table 2 shows the factors that were listed. These risk 
factors and follow up for fracture and death were asked for in the eleven cohorts.  
 
Then the cohorts and the statistical methods described in Methods were used when the list of 
risk factors were worked through.  
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Table 2. Potential risk factors 
Age Milk intake Mental status 
Height BMD Age at menopause 
Weight Ultrasound HRT use 
BMI Bone markers Oral contraceptive 
Previous fracture Glucocorticoids Hysterectomy 
Maternal history of fracture Rheumatoid arthritis Oopherectomy 
Paternal history of fracture Stroke Neuromuscular data 
Sibling history of fracture Diabetes Liability to fall 
Smoking Hyperthyroidism  
Alcohol use Osteoarthritis  
 
Some risk factors were too heterogeneous in construct between cohorts; examples were 
mental status, neuromuscular data and liability to fall. For instance there were three cohorts 
that had some information on neuromuscular risk factors. For one cohort it was a question 
about multiple sclerosis or Parkinson disease, in another it was only on Parkinson disease and 
for the third it was the score from Rose Questionnaire. These three potential risk factors are 
just analysed for each cohort and the results were not merged. The conclusion was that there 
were not enough data and too heterogeneous to consider as a risk factor for fracture. 
 
For some risk factors the results were merged, but they had no significant importance for 
fracture. Table 3 shows the hazard ratios with 95% confidence interval for the risk factors that 
were not significantly associated with fracture. For brevity, the hazard ratios for hip fracture 
are shown in Table 3, though the outcome of any fracture and osteoporotic fracture was also 
assessed (and also non-significant). Men and women were also analysed separately though the 
data are not shown. The number of individuals contributing to each hazard ratio differs since, 
for example, there were 10 cohorts that had information on menopause but there were 4 
cohorts that had information on oral contraceptives. From the material available, it was 
concluded that there was no evidence that these risk variables had any significant importance 
for fracture. 
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Table 3. Factors that didn’t have significant importance for risk of hip fracture. Hazard ratios 
for men and women together (not adjusted for BMD). 
  HR 95% CI 
Low milk intake 1.17a 0.91-1.50 
Age at menopause 1.00b 0.99-1.02 
HRT use 1.32c 0.93-1.87 
Oral contraceptives 0.86c 0.52-1.41 
Hysterectomy 1.08d 0.86-1.36 
Oopherectomy 1.01d 0.69-1.49 
a Less than 1 glass per day 
b per year change in age 
c users versus non-users 
d having the condition versus not 
 
Secondary osteoporosis. Apart from the use of glucocorticoids, the prevalence of secondary 
causes of osteoporosis is low in population-based cohorts. In addition, few cohorts had 
information on secondary osteoporosis. For instance, 3 cohorts had information on 
rheumatoid arthritis and 5 cohorts had information on stroke. The information available is 
summarised in Table 4 for hip fracture risk. The outcome of any fracture and osteoporotic 
fracture was also assessed. Rheumatoid arthritis was taken as a surrogate for secondary 
osteoporosis, since it was the only factor that has significant importance for fracture. For any 
fracture it was a significant factor (HR=1.45; 95% CI= 1.16-1.80) and for osteoporotic 
fracture (1.56; 1.20-2.02). The risk persisted after adjusting for glucocorticoid use and prior 
fracture. The hazard ratio was lower but still significant after adjusting for BMD. 
 
Biochemical markers of bone turnover (bone markers). There are situations where enough 
data could not be found. One example is bone markers. Data were available from 4 cohorts. 
Only one of them had data for men. Table 5 shows the hazard ratios for women. It is seen that 
resorption markers were of significant importance for hip fracture for women. When adjusted 
for BMD, the hazard ratio was 1.39 (1.10-1.77). These data, undertaken on a collection of 
markers, indicate the potential importance of resorption markers for fracture risk assessment 
but the data are too few in an international perspective to consider their inclusion in FRAX. 
Notwithstanding, this is an important area for future research.  
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Table 4. Secondary osteoporosis. Hazard ratios for hip fracture for men and women together 
(not adjusted for BMD). 
 HRa 95% CI 
Rheumatoid arthritis 1.95 1.11-3.42 
Stroke 1.20 0.78-1.84 
Diabetes 1.22 0.88-1.69 
Hyperthyroidism 1.12 0.48-2.61 
Osteoartritis 0.76 0.57-1.02 
a having the condition versus not 
 
Table 5. Bone markers. Hazard ratios for hip fracture for women together (not adjusted for 
BMD). 
 HRa 95% CI 
Resorption markers 1.62 1.28-2.04 
Formation markers 1.15 0.73-1.81 
a highest quartile versus the rest 
 
Quantitative ultrasound (QUS) and Peripheral BMD. The most widely evaluated assessments 
are broad-band ultrasound attenuation (BUA) and speed of sound (SoS) (or ultrasound 
velocity) at the heel. There were only 2 cohorts having data on QUS. No cohort had data for 
men. Table 6 shows that BUA and SoS is of significant importance for the risk of hip fracture 
in women. For the outcome of any fracture and osteoporotic fracture there were data from just 
one cohort. Thus, QUS is also a potential technique that provides information on fracture risk 
for the research agenda rather than for its incorporation in FRAX.  
 
There were three cohorts with information on peripheral BMD. All measurements were from 
the forearm. There was only one cohort in which there were data for men. Table 6 shows that 
peripheral BMD is of significant importance for the risk of hip fracture in women.  
 
Femoral neck BMD. Femoral neck BMD was available in all but two cohorts. Figure 1 shows 
the hazard ratios per 1 standard deviation change in BMD. There were no significant 
difference between men and women. Thus, the data for men and women were merged. The 
combined hazard ratio for men plus women for hip fracture was 2.18 (2.01-2.38) and for 
osteoporotic fracture was 1.55 (1.48-1.63) 70.  
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Table 6. Ultrasound and peripheral BMD. Hazard ratios for hip fracture for women together 
(not adjusted for BMD at femoral neck). 
 HRa 95% CI 
BUA 1.74 1.53-1.97 
SoS 1.50 1.31-1.70 
Peripheral BMD 1.30 1.15-1.48 
a per 1 standard deviation change 
 
Figure 1: Gradient of risk (hazard ratio per 1 SD decrease) for femoral neck BMD for 
osteoporotic and hip fracture. The 95% confidence intervals are shown by the vertical lines. 
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BMD and age. The effect of BMD on fracture risk was dependent on age. For osteoporotic 
fracture there was an increase of risk with increasing age, as shown in Figure 2 for men and 
women combined. At the age of 50 years the hazard ratio was 1.37 (1.23-1.52) and at the age 
of 80 it increased significantly to 1.62 (1.54-1.71). For hip fracture, the opposite pertained in 
that the gradient of risk decreased with increasing age. At the age of 50 years, the hazard ratio 
was 3.68 (2.61-5.19) and at the age of 80 years was 2.28 (2.09-2.50). The decrease in GR with 
age was also significant. 
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Figure 2: Gradient of risk (RR/SD) for fracture for the interaction with age (thin lines - 95% 
confidence interval) 
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BMD and BMD. For osteoporotic fracture (and any fracture) there was a higher gradient of 
risk the lower the BMD. This effect was significant. At a Z-score of –4 the hazard ratio was 
2.10 per SD (1.63-2.71) and at a Z-score of –1 the risk was 1.73 per SD (1.59-1.89). A similar 
but less pronounced and non-significant effect was observed for hip fractures. 
 
Thus, BMD is a risk factor for fracture of substantial importance and is similar on both sexes. 
Its use should, however, take account of the variations in predictive value with age and BMD. 
 
Weight, height and BMI. Analysis were done of all three factors. Weight and BMI had almost 
the same results but height was rather weak as a risk factor for fracture . In addition, average 
body weight was variable between cohorts. These problems were reduced somewhat by the 
use of BMI which was chosen, therefore for further analysis.  
 
BMI. All cohorts had data on BMI. Figure 3 shows the hazard ratios per unit increase in BMI. 
There were no significant difference between men and women. Thus men and women can be 
merged and the overall hazard ratio for men and women combined for hip fracture was 0.93 
(0.91-0.94). For osteoporotic fracture it was 0.97 (0.96-0.98). After adjusting for BMD these 
hazard ratios became 1.00 (0.99-1.01) for osteoporotic fracture and 0.98 (0.96-0.99) for hip 
fracture 71. Thus low BMI provides a risk factor for fracture, but in the presence of 
information on BMD, low BMI no longer contributed to facture risk. 
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Figure 3: Hazard ratio per unit increase for BMI for osteoporotic and hip fracture. The 95% 
confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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BMI and age. However the effect of BMI on fracture was dependent on age (Figure 4). For 
osteoporotic fracture there was a significant increase in the gradient of risk with increasing 
age, meaning that the hazard ratio for fracture was more pronounced the older the individual. 
In contrast, for hip fracture the gradient of risk decreased with increasing age, although this 
trend was not significant. Overall, the pattern of the relationship between BMI and age was 
similar to that observed for BMD (see Figure 2). 
 
BMI and BMI. The contribution of BMI to fracture risk was much more marked at low values 
of BMI than at values above the median (Figure 5). This non-linear relation of risk with BMI 
was most marked for hip fracture risk. Thus, low BMI constitutes a risk factor for fracture to 
an extent much greater than high BMI protecting against fracture. These data show that there 
is no conflict between advice for weight control for the prevention of diabetes or 
cardiovascular disease, and that for the prevention of osteoporotic fractures. 
 
In summary, low BMI confers a risk of fracture of substantial importance that is largely 
independent of sex, but dependent on age and BMD. The significance of BMI as a risk factor 
varies according to the level of BMI.  
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Figure 4: Hazard ratio per 1 unit increase for BMI for fracture for the interaction with age in 
men and women combined (thin lines - 95% confidence interval) 
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Figure 5: Hazard ratio versus 25 kg/m2 for fracture for the interaction with BMI 
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Ever use of oral glucocorticoids. Previous glucocorticoid use was associated with a 
significantly increased risk of osteoporotic fracture and hip fracture (Figure 6). There was no 
significant difference in risk between men and women. Thus data for men and women were 
merged and the overall hazard ratio of ever use of glucocorticoids versus non-users was 1.65 
(1.42-1.90) for osteoporotic fracture and 2.31 (1.67-3.20) for hip fracture. The estimate of 
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relative risk was higher at younger ages but not significantly so. The risk was marginally and 
not significantly downward adjusted when BMD was included in the model. The risk was 
independent of prior fracture 72.  
 
Figure 6: Hazard ratio for ever use of glucocorticoids for osteoporotic and hip fracture. The 
95% confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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Thus, prior and current exposure to glucocorticoids confers an increased risk of fracture that 
is of substantial importance beyond that explained by the measurement of BMD. The effect 
was independent of age, sex and previous fracture. 
 
Maternal, paternal and sibling history. Data were available for a family history in either 
parent and in siblings and each were analysed separately and in different combinations. In 
addition data were available for a family history of hip fracture or any osteoporotic fracture. 
When maternal, paternal and sibling history was combined, hazard ratios were marginally 
higher, but similar to the combination of maternal or paternal history alone. A parental history 
was chosen as the index variable since the probability of a sibling varies markedly around the 
world and is less appropriate, therefore, for use in an international context. 
Maternal or Paternal history. A parental history of any fracture was associated with a 
significantly increased risk of osteoporotic fracture and hip fracture (Figure 7). No significant 
difference in risk was seen between men and women so that the data for men and women 
were merged. The overall hazard ratio for osteoporotic fracture was 1.18 (1.06-1.31) and for 
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hip fracture 1.49 (1.17-1.89). The hazard ratio was higher at younger ages but not 
significantly so. When the risk variable was confined to a parental history of hip fracture 
(rather than any fracture), the hazard ratio was larger. A family history of hip fracture in 
parents was associated with a significant risk of osteoporotic fracture 1.54 (1.25-1.88) and hip 
fracture 2.27 (1.47-3.49). The risk was not significantly changed when BMD was added to the 
model 73. 
 
Figure 7: Hazard ratio for parental history of any fracture for osteoporotic and hip fracture. 
The 95% confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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Thus, a parental history of fracture (particularly a family history of hip fracture) confers an 
increased risk of fracture that is independent of BMD. The effect is independent of age and 
sex. 
 
Previous fracture. A previous fracture history was associated with a significantly increased 
risk of fracture (Figure 8). There was no significant difference in hazard ratio between men 
and women and the data for men and women were merged. The hazard ratio for osteoporotic 
fracture was 1.86 (1.72-2.01) and for hip fracture was 1.85 (1.58-2.17). The hazard ratio was 
marginally downward adjusted when account was taken of BMD. The hazard ratio was stable 
with age except in the case of hip fracture where the hazard ratio decreased significantly with 
advancing age, from 5.04 (2.66-9.56) at 50 years of age to 1.90 (1.58-2.28) at the age of 80 
years 74. 
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Figure 8: Hazard ratio for previous fracture for osteoporotic and hip fracture. The 95% 
confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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In conclusion, a previous history of fracture confers an increased risk of fracture of substantial 
importance beyond that explained by measurement of BMD. The effect is dependent of age 
and independent of sex. 
 
Current smoking. Data were available for both current smoking and ever smoking. The hazard 
ratios were higher for current smoking than ever smoking. Current smoking was associated 
with a significantly increased risk of fracture compared to non-smokers (Figure 9). Hazard 
ratios were significantly higher in men than in women for all fractures and for osteoporotic 
fractures, but not for hip fracture. Hazard ratio was marginally downward adjusted when 
account was taken of BMD but remained significantly increased. For osteoporotic fracture, 
the hazard ratio increased with age, but decreased with age for hip fracture. None of these 
effects were significant (p>0.30)75. 
 
Thus, current smoking is associated with a significantly increased risk of fracture compared 
with non-smokers. The effect is dependent of sex and independent of age. 
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Figure 9: Hazard ratio for current smoking for osteoporotic and hip fracture. The 95% 
confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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Alcohol intake. The last risk factor to be handled was alcohol intake. The unit is average units 
of consumption per day. A unit of alcohol is equivalent to 8g in the UK, though varies 
somewhat in different countries. When alcohol intake was considered as a continuous 
variable, there was no significant increase in risk observed at intakes of 2 units or less daily. 
For this reason, intake of alcohol was dichotomised using a cut off of 3 or more units per day 
(Figure 10). High intake of alcohol, defined in this way, was associated with a significant 
increase in osteoporotic and hip fracture risk. Hazard ratios were moderately but not 
significantly higher in men than in women and the data for men and women were merged. 
The overall hazard ratio for those drinking more than 2 units per day versus those who did not 
was 1.38 (1.16-1.65) for osteoporotic fracture is and 1.68 (1.19-2.36) for hip fracture. There 
was no significant interaction with age or with BMD 76. 
 
Thus, reported intake of alcohol confers a risk of some importance beyond that explained by 
BMD. The effect is independent of age and sex. 
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Figure 10: Hazard ratio for alcohol intake >2 units per day for osteoporotic and hip fracture. 
The 95% confidence intervals are showed with the vertical lines. Not adjusted for BMD. 
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Risk factors for fracture. It is concluded that the risk factors detailed above confer risks of 
importance beyond that explained by BMD. An exception is BMI. Their validation on an 
international basis permits their use in case finding strategies. The following risk factors were 
selected on the basis of their international validity and the ease with which the risk factor 
could be utilised in clinical practice. 
 
• BMD at femoral neck 
• BMI 
• Glucocorticoid exposure 
• Family history 
• Previous fracture 
• Smoking 
• Alcohol intake 
• Secondary osteoporosis 
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Interactions. Interactions between the risk variables were investigated. Our findings are 
summarized in table 7.  
 
Table 7. Significant interactions determined from meta-analyses of risk factors for hip 
fracture (HF) or any osteoporotic fracture (OPF). 
 BMD  Age  Variable*  Sex  Time 
Risk factor HF OPF  HF OPF  HF OPF  HF OPF  HF OPF 
               
BMI - -  - +  + -  - -  + - 
Prior fracture - -  + -     - -  - - 
Glucocorticoids - -  - -     - -  - - 
Family history _ _  - -     - -  - - 
Smoking - -  - -     - -  - - 
Rheumatoid arthritis - -  - -     - -  - - 
Alcohol - -  - -     - -  - - 
BMD    + +  - +  - -  - - 
- denotes no effect (p>0.05); + denotes a significant interaction. 
* denotes an interaction of the variable with the variable, e.g. BMI×BMI. 
 
Table 8 shows the risk variables are present in the different cohorts used to construct the 
FRAX models 
 
To calculate the 10 year probability of hip and osteoporotic fracture six hazard functions are 
needed. These were estimated by Poisson regression. The six hazard functions were  
- for the risk of osteoporotic fracture without hip fracture without BMD in the model,  
- for the risk of osteoporotic fracture without hip fracture with BMD in the model,  
- for the risk of hip fracture without BMD in the model,  
- for the risk of hip with BMD in the model,  
- for the risk of death without BMD in the model  
- for the risk of death with BMD in the model. 
 
Those variables that did not have significant importance in the multivariable models were 
deleted. The final results are shown in table 9.  
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Table 8. Risk factors examined by cohort. 
Cohort BMI Family 
history 
BMD Gluco-
corticoids 
Prior 
fracture 
Smoking Alcohol Rheumatoid 
arthritis 
EVOS/EPOS + + + + + + - - 
CaMos + + + + + + + + 
Rochester + + + + + + - - 
Rotterdam + + + + + + + - 
DOES + + + + + + + + 
Gothenburg I + - + - + + - - 
Gothenburg II + + + + + + - - 
Hiroshima + - + + + + - - 
Sheffield + + + + + + - + 
Kuopio + - + - + + - - 
OFELY + - + - + - - - 
 
Table 9 
Variables in the hazard  
function for fracture 
Variables in the hazard  
function for death 
Current time Current time 
Min(Current age, 65) Min(Current age, 65) 
Max (Current age-65,0) Max (Current age-65,0) 
Sex (1/2) Sex (1/2) 
Min (BMI, 25) Min (BMI, 25) 
Max (BMI-25,0) Max (BMI-25,0) 
Previous fracture (0/1) Current smoke (0/1) 
Mother/Father (0/1) Glucocorticoids (0/1) 
Current smoke (0/1) Sex x current age 
Glucocorticoids (0/1) BMD 
RA (0/1)  
Alcohol (0/1)  
Sex x current age  
Previous fracture x min(current age,80)  
Mother/Father x max(0,min(age-65,10))  
Min (BMD, 0)  
Max (BMD,0)  
BMD x current age  
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The hazard functions were estimated by use of the eleven cohorts from different countries and 
the data calibrated to the epidemiology of a specific country. By considering all variables 
except age, a risk score was calculated by multiplying each variable by the corresponding beta 
coefficient and adding the products. A 10 year probability is then calculated. 
 
Table 10 shows the ten-year probability fracture for men and women in Sweden.  
 
Table 10. Ten-year probability of fracture (%) at the sites shown for men and women with a 
BMI of 24 kg/m2 according to age and the presence or absence of a single risk factor in the 
absence of BMD. 
 Osteoporotic fracturea  Hip fracture 
 50 60 70 80  50 60 70 80 
(a) Men          
No clinical risk factors 3.3 5.1 7.8 12  0.3 0.8 2.8 7.1 
Parental history of hip fracture 6.6 9.6 13 26  0.3 1.1 5.8 22 
Current cigarette smoking 3.5 5.5 8.6 14  0.4 1.2 3.9 9.1 
Alcohol intake >2 units daily 4.0 6.2 10 16  0.4 1.3 4.2 11 
Rheumatoid arthritis 4.5 7.0 11 18  0.5 1.5 4.8 12 
Oral glucocorticoids 5.4 8.2 12 18  0.6 1.7 5.2 12 
Prior fragility fracture 7.2 10 15 19  1.0 2.4 5.8 11 
          
(b) Women          
No clinical risk factors 4.1 7.6 14 26  0.4 1.3 4.7 13 
Parental history of hip fracture 8.1 14 23 47  0.5 1.7 9.9 38 
Current cigarette smoking 4.4 8.3 16 29  0.6 2.0 6.9 18 
Alcohol intake >2 units daily 5.0 9.3 18 33  0.6 2.0 7.1 19 
Rheumatoid arthritis 5.6 10 20 36  0.7 2.3 8.2 22 
Oral glucocorticoids 6.8 13 23 38  0.9 2.8 9.6 23 
Prior fragility fracture 9.0 15 26 39  1.6 3.8 9.8 20 
aClinical spine, hip, humeral or forearm fracture. 
 
Table 11 shows the ten-year probability of having a fracture for men and women in Sweden. 
 
 
 
  
  
  39 
Table 11. Ten-year probability of fracture (%) at the sites shown for men and women with a 
BMI of 24 kg/m2 according to age and the BMD T-score, no clinical risk factors present. 
 Osteoporotic fracturea  Hip fracture 
 50 60 70 80  50 60 70 80 
(a) Men          
BMD T-score 0 3.2 4.3 5.3 6.2  0.2 0.4 0.9 2.1 
BMD T-score -1 4.2 5.7 7.1 8.2  0.6 1.1 2.1 3.6 
BMD T-score -2 6.6 8.9 11 12  2.2 3.2 4.8 6.5 
BMD T-score -2.5 8.9 12 14 15  4.2 5.4 7.3 8.8 
          
(b) Women          
BMD T-score 0 3.7 5.6 7.6 10  0.1 0.2 0.6 1.7 
BMD T-score -1 4.3 6.7 9.8 14  0.4 0.7 1.6 3.6 
BMD T-score -2 6.3 9.7 14 19  1.4 2.2 4.2 7.4 
BMD T-score -2.5 8.1 12 18 24  2.7 4.0 6.8 11 
aClinical spine, hip, humeral or forearm fracture. 
 
The 10 year probabilities are based on a risk score which was built as showed in table 8 
(minus the coefficients for time and age). Table 12 shows the gradient of risk per SD change 
in score with the use of BMD, clinical risk factors or the combination. Note that the gradient 
of risk was age-dependent. For hip fracture risk, higher gradients if risk were observed in 
younger individuals, whereas the opposite pertained for the risk of other osteoporotic fracture. 
 
Since the age distribution varied from cohort to cohort, the gradients of risk in individual 
cohorts were age-standardised. The index cohorts used to create FRAX were compared with 
information from the validation cohorts collected (Table 13). The performance of the risk 
score in the validation cohorts was similar to that found in the source cohorts. 
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Table 12. Gradients of risk per SD change in risk score (with 95% confidence interval) with 
the use of BMD, clinical risk factors or the combination. 
 Gradient of risk 
   Clinical risk  Clinical risk 
Age BMD only  factors alone  factors + BMD 
      
(a) Hip fracture 
50 3.68 (2.61-5.19)  2.05 (1.58-2.65)  4.23 (3.12-5.73) 
60 3.07 (2.42-3.89)  1.95 (1.63-2.33)  3.51 (2.85-4.33) 
70 2.78 (2.39-3.23)  1.84 (1.65-2.05)  2.91 (2.56-3.31) 
80 2.28 (2.09-2.50)  1.75 (1.62-1.90)  2.42 (2.18-2.69) 
90 1.70 (1.50-1.93)  1.66 (1.47-1.87)  2.02 (1.71-2.38) 
      
(b) Other osteoporotic fractures 
50 1.19(1.05-1.34)  1.41 (1.28-1.56)  1.44 (1.30-1.59) 
60 1.28 (1.18-1.39)  1.48 (1.39-1.58)  1.52 (1.42-1.62) 
70 1.39 (1.30-1.48)  1.55 1.48-1.62)  1.61 (1.54-1.68) 
80 1.54 (1.44-1.65)  1.63 (1.54-1.72)  1.71 (1.62-1.80) 
90 1.56 (1.40-1.75)  1.72 (1.58-1.88)  1.81 (1.67-1.97) 
 
Table 13. Gradient of risk of original and validation cohorts standardised to the age of 70 
years. 95% confidence intervals are shown in parentheses. 
 Hip fractures  Other osteoporotic fractures 
Cohort without BMD with BMD  without BMD with BMD 
      
Geelong I 1.88 (1.07-3.29) 1.71 (0.74-3.96)  1.34 (1.12-1.61) 1.57 (1.31-1.88) 
Geelong II 1.50 (1.05-2.13) 3.40 (1.99-5.80)  1.30 (1.14-1.48) 1.54 (1.36-1.76) 
OPUS 2.48 (1.26-4.91) 2.09 (0.98-4.47)  1.32 (1.08-1.62) 1.38 (1.15-1.65) 
York 2.05 (1.13-3.72) - (-)  1.74 (1.37-2.21) - (-) 
PERF 1.28 (1.01-1.62) 2.72 (1.43-5.16)  1.14 (1.05-1.23) 1.19 (1.05-1.35) 
SOF 1.58 (1.34-1.87) 2.21 (1.79-2.73)  1.24 (1.15-1.34) 1.31 (1.20-1.42) 
THIN 1.54 (1.45-1.63) - (-)  1.29 (1.26-1.32) - (-) 
EPIDOS 1.70 (1.18-2.44) 2.89 (1.98-4.21)  1.41 (1.11-1.78) 1.47 (1.17-1.86) 
Miyama 2.87 (0.98-8.37) 3.07 (0.97-9.64)  3.50 (2.42-5.07) 2.80 (2.06-3.80) 
SEMOF 1.76 (1.03-3.01) 2.18 (1.27-3.74)  1.32 (1.10-1.58) 1.44 (1.16-1.79) 
WHI 1.54 (1.43-1.66) 2.44 (1.85-3.21)  1.26 (1.23-1.29) 1.46 (1.35-1.58) 
      
Original cohorts 1.84 (1.65-2.05) 2.91 (2.56-3.31)  1.55 (1.48-1.62) 1.61 (1.54-1.68) 
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III: BMD – death 
The principal aim of paper III was to examine the relationship between BMD and death in 
men. Standardised BMD at all sites was significantly lower in men who subsequently died 
compared with men who remained alive during the follow-up. The hazard ratio for 1standard 
deviation decrease in total hip BMD (GR) was 1.28 (95% CI 1.15-1.43) , adjusted for age and 
time since baseline and 1.27 (95% CI 1.14-1.42) when adjusted for age, time since baseline, 
cancer, angina, diabetes, systolic blood pressure and general health.  
 
The relation between BMD and death was, however more complex than a simple gradient of 
risk. In figure 11 the dashed diagonal line describes the relation found between death and total 
hip BMD when it was assumed that there is a constant gradient of risk of 1.27 all over the 
observed range of BMD. The bold line describes the relationship when the hazard function is 
described with spline functions (knots in the 1st, 10th, 90th and 99th percentiles of BMD). There 
was a significant difference between the slope of the spline function below and above the 25th 
percentile (p=0.020). 
 
IV: Vitamin D 
There are some analogies to be drawn from the study of BMD and death and the findings in 
paper IV in that a non-linear relation was established between serum 25(OH)D and the risk of 
death. Serum 25(OH)D was significantly lower in men who subsequently died compared with 
men who remained alive during the follow-up. The hazard ratio for a 1SD decrease in 
25(OH)D (GR) was 1.16 (95% CI 1.07-1.26), adjusted for age and time since baseline. When 
adjusted for age, time since baseline, total hip BMD, cancer, angina, diabetes, outdoor 
activity, physical activity, number of medication and general health the GR was 1.06 (95% CI 
0.98-1.16).  
 
As was the case for BMD and death, increased mortality was confined to low values of the 
risk variable (Figure 12). When comparing the fit of the models with and without allowing for 
non-linearity (and interaction with time- see below), the former had a significantly better fit 
using the maximum-likelihood test (p=0.0015). Thus, the mortality hazard was not increased 
above values of 60-75 nmol/l of 25(OH)D (threshold dependent on the model used).  
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Figure 11 The hazard function of death (momentary risk) and 95% confidence interval depending on 
total hip BMD for a man aged 75 years after 2 years from baseline, with no history of cancer, angina 
or diabetes and with an average systolic blood pressure and self-estimated general health. The dashed 
diagonal line represents the relationship assuming that the gradient of risk is the same all over the 
whole range of BMD. The vertical dashed lines in the figure represent the 1st, 25th, 50th, 75th and the 
99th percentiles.  
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Over and above this appearance of a threshold effect, the impact of low 25(OH)D values 
appeared to attenuate with time. The maximum effect of vitamin D on mortality was at 3.25 
years after baseline. Figure 12 shows the death risk per 100 person years for different values 
of 25(OH)D at 3 years of follow up and at 6 years since baseline. The relationship between 
mortality and 25(OH)D was described with spline functions with knots in 10th, 50th and 90th 
percentiles.  
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Figure 12. The hazard function of death (momentary risk) and 95% confidence intervals 
according to serum 25(OH)D for a man aged 75 years after 3 years of follow up ( continuous 
lines) after 6 years of follow up (dotted lines). Diabetes is set to no like outdoor activity. 
Physical activity, BMD and general health is set to average value of the cohort. The vertical 
dashed lines in the figure represent the 1st, 10th, 50th, 90th and 99th percentiles.  
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V: Adiponectin 
The Mr Os cohort was also used to examine a novel potential index of fracture risk in serum 
adiponectin. At the time of the analysis, the 999 men aged 70-81 years had been followed for 
up to 7.4 years, with an average follow up of 5.2 years. Of these, 150 men had a fracture 
during follow up. Adiponectin was significantly lower in men who subsequently fractured 
compared with men who did not fracture during the follow-up. The hazard ratio for 1standard 
deviation increase in adiponectin (GR) was 1.44 (95% CI 1.27-1.64), adjusted for age and 
time since baseline and 1.32 (95% CI 1.15-1.52) adjusted for age, time since baseline, BMD 
total hip, previous fracture and general health. 
 
Figure 13 shows the relationship between adiponectin and fracture risk with spline functions 
(knots in 10th, 50th and 90th percentiles). Fracture risk increased with increasing values of 
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serum adiponectin but the association was not significant at values below 18 μg/ml. Above 
threshold value the GR was 1.59 (95% CI 1.23-2.05).  
 
When the interaction between serum adiponectin and the time since baseline was entered in 
the Poisson model, the interaction was significant (p=0.020). The gradient of fracture risk per 
1 SD (GR) decreased with time since baseline measurements (Figure 14). 
 
Figure 13. The hazard function of fracture (momentary risk) assessed and 95% confidence 
intervals according to baseline serum adiponectin for a man where age was set to 75 years, the 
time since baseline was set to 2 years of follow up. Previous fracture was set to no and BMD 
and general health is set to the average value of the cohort. The vertical dashed lines in the 
figure represent the 1st, 10th, 50th, 90th and 99th percentile. 
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Figure 14. Gradient of risk per 1 SD (95% confidence interval) for the association between 
serum adiponectin and the risk of any fracture  
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Discussion 
FRAX® I-II 
Many risk factors for fracture are known and could be used to develop risk engines for 
fracture. FRAX® is an example of a risk engine for fracture that was developed with use of 
international population-based prospective cohorts.. The obvious application of FRAX® is in 
the assessment of individuals to identify patients suitable for pharmacological intervention 
and it has been widely used for this purpose. The web site, launched in 2008, currently 
receives about 200,000 hits per working day. Because of the ability of internet and computers 
the algorithms behind the risk engines don’t have to be simple. Following regulatory review 
by the US Food and Drug Administration, FRAX has been incorporated into DXA scanners to 
provide FRAX probabilities at the time of DXA scanning. FRAX is incorporated (or in the 
process) in many clinical guidelines 77-87 and has also been used for health economic 
calculations88 89.  
 
FRAX® has also been extensively validated 15 90-99. There have been calls to add variables to 
FRAX® and of course that could be valuable if risk prediction can be shown to be improved. 
To add risk factors with the same scientific rigour as the current risk factors included in 
FRAX, will demand the study of several international prospective cohorts of normal 
populations including the new risk factor and the established risk factors. This is required to 
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investigate the interactions between all risk factors and their relation to time since baseline. 
Some authors suggest that FRAX® variously overestimates or underestimates fracture risk 
but in the light of the different fracture incidence within each country, both ethnic-specific 
differences100-102 and differences between urban and rural communities103-110 it would be 
surprising to find identical fracture hazards when regional cohorts are examined. For this 
reason, the finding of modest differences (up to two-fold) in expected and observed fracture 
rates from small cohorts should not be used to derive a conclusion that a FRAX model is not 
well calibrated, particularly if based on national fracture and mortality statistics.  
 
The use of FRAX® with the generation of a number does not, however, replace clinical 
judgement. Several of the clinical risk factors identified take no account of dose-response, but 
give risk ratios for an average dose or exposure. By contrast, there is good evidence that the 
risk associated with excess alcohol consumption, cigarette smoking and the use of 
glucocorticoids is dose-responsive 75 76 109. In addition, the risk of fracture increases 
progressively with the number of prior fractures 111 112. These limitations should be recognised 
when interpreting the FRAX® result in the clinic. A guide for the effect of doses of 
glucocorticoids to FRAX® has been developed113.  
 
At present the FRAX® tool limits BMD to that measured at the femoral neck. This is because 
of the wealth of data available for this site. There are, however, other bone measurements that 
provide information on fracture risk. These include BMD at other skeletal sites 114, 
ultrasonography 115, quantitative computed tomography 116 and the biochemical indices of 
bone turnover. A guide for the effect of differences between lumbar spine BMD and femoral 
neck BMD to FRAX® has been developed117. 
 
For these reasons, the FRAX® tool should not be considered by physicians as a gold standard, 
but rather as a platform technology on which to build as new validated risk indicators become 
available. Notwithstanding, the present model provides an aid to enhance patient assessment 
by the integration of clinical risk factors alone and/or in combination with BMD. 
  
III-V 
One reason for investigating risk factors for fracture and death is that risk engines can be 
developed. To be able to make a good risk engine many aspects of the risk factor must be 
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examined, such as the risk factors dependence on time, age, other risk factors and if the 
association between the risk factor and the endpoint is different for different values of the risk 
factor (a non-linear association). For the association between BMD and mortality, a non-
linear association was shown in elderly men. For the association between vitamin D and 
mortality, a non-linear association was also shown that also decreased in importance with the 
time since baseline measurement in elderly men. Additionally, the association between 
adiponectin and fracture risk was dependent on time since baseline measurement. 
 
Our findings that the association between vitamin D and mortality and the association 
between adiponectin and fracture is dependent on time may explain, in part, the disparate 
conclusions reported in previous studies that have examined these relationships. Whereas the 
finding of a significant relationship is consistent with our results, so too is the absence of a 
significant effect, particularly after a longer follow up.  
 
The most obvious limitation of these studies is that the cohort is limited to elderly men (70-80 
years) and the relationships among women or men at other ages is not known. The 
participation rate was 45% and there is likely to be a healthy selection bias. A healthy 
volunteer bias is expected to converge with the general population over time, and evidence for 
such a bias are shown in the different models presented. This is a factor to be aware of when 
interpreting the result, but since ‘time since baseline’ is in the model, this effect was in part 
adjusted for. One strength of these studies is the detail of the baseline assessment so potential 
confounders can be examined and adjustment made where appropriate.  
 
In conclusion, there are significant relationships between BMD and mortality, vitamin D and 
mortality and between adiponectin and fracture. The relationship between BMD and mortality 
and between vitamin D and mortality are both non-linear and the relationship between vitamin 
D and mortality is dependent on time since baseline. The relationship between adiponectin 
and fracture risk is also dependent on time. These data using advanced analytic techniques, 
suggest the increased risk of death is much greater at low values of measured BMD, at least in 
elderly men. If these findings were confirmed in other cohorts and in women, this would have 
marked implications for fracture risk assessment in that their accuracy could be improved by 
accommodating this non-linear relationship. This analysis also has important implications for 
the choice of risk variables that might be incorporated into future models. In selecting novel 
  
  
  48 
risk factors, it will be important to determine their operating characteristics with the passage 
of time, particularly in models such as FRAX that use a 10 year time horizon 
 
Conclusions 
In conclusion, the findings in this thesis produced a detailed risk assessment tool for fracture 
(FRAX) which is unique in the field since it is based on international cohorts, externally 
validated and has taken death risk into account. The tool is however limited by the risk 
variables reported in the cohorts and could in the future be enhanced by inclusion of other risk 
variables in the hazard function for death and fracture. As a start of investigating new risk 
variables for men the thesis has investigated the association between BMD and death, vitamin 
D and death and adiponectin and fracture. Those risk variables could be important for the 
construct of a future risk assessment tool if cohorts are developed that including these risk 
variables and the clinical risk factors used in FRAX and BMD for men and women over a 
wider range of age.  
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Erratum: 
 
Paper I: 
· Reference 14 should be: Stenstrom M, Olsson J, Mellstrom D. Thyroid hormone 
replacement is not related to increased risk of osteoporosis. Osteoporos Int 
2000;11(suppl 2):S144. 
 
Paper II: 
· In table 1 the names Gothenburg I and II should change places. 
· Page 1042 right panel row 12 the formula should be exp([log(2.8)2 + log(1.8)2]1/2) = 
3.3 
· Reference 32 should be: Stenstrom M, Olsson J, Mellstrom D. Thyroid hormone 
replacement is not related to increased risk of osteoporosis. Osteoporos Int 
2000;11(suppl 2):S144. 
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